Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SAVA 
Cassava Sciences Inc (SAVA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: SAVA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.94% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.54M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta -2.02 | 52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 |
52 Weeks Range 1.15 - 42.20 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -59.03% | Return on Equity (TTM) -70.6% |
Valuation
Trailing PE - | Forward PE 151.52 | Enterprise Value -35631025 | Price to Sales(TTM) - |
Enterprise Value -35631025 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.26 | Shares Outstanding 48307900 | Shares Floating 43475174 |
Shares Outstanding 48307900 | Shares Floating 43475174 | ||
Percent Insiders 12.79 | Percent Institutions 33.05 |
Upturn AI SWOT
Cassava Sciences Inc
Company Overview
History and Background
Cassava Sciences, Inc. (SAVA) was founded in 1998. Initially focused on detecting diseases, it shifted its focus to neurodegenerative diseases, particularly Alzheimer's, in the late 2000s. Its key milestone is the development of Simufilam, its investigational drug for Alzheimer's disease.
Core Business Areas
- Pharmaceutical Development: Cassava Sciences focuses primarily on developing drugs for neurodegenerative diseases, with a focus on Alzheimer's disease. This includes research, clinical trials, and regulatory approval processes.
Leadership and Structure
Remi Barbier serves as President and CEO. The organizational structure is typical of a small biotech company, with research and development as the core functional units.
Top Products and Market Share
Key Offerings
- Simufilam: Simufilam is Cassava Sciences' lead drug candidate for Alzheimer's disease. It is currently undergoing clinical trials. There is no current revenue or market share as the drug is not yet approved. Competitors include Biogen (LEQEMBI), Eisai (LEQEMBI), and Eli Lilly (donanemab - in development).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the segment focused on Alzheimer's disease, is highly competitive and regulated. There is a significant unmet need for effective Alzheimer's treatments.
Positioning
Cassava Sciences is a clinical-stage biotechnology company aiming to provide an Alzheimer's drug through a different mechanism of action than its competitors. Success depends on clinical trial outcomes and regulatory approvals.
Total Addressable Market (TAM)
The global Alzheimer's disease market is projected to reach hundreds of billions of dollars annually. Cassava's market position depends entirely on successful drug approval and subsequent market penetration.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for Simufilam
- Potentially disease-modifying approach
- Focused Alzheimer's drug development
Weaknesses
- Reliance on a single drug candidate
- Limited financial resources compared to larger competitors
- Clinical trial risks and regulatory uncertainty
Opportunities
- Successful clinical trial outcomes
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to address other neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory disapproval
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ESALY
Competitive Landscape
Cassava Sciences faces an uphill battle against larger, more established pharmaceutical companies. Its advantage lies in its novel mechanism of action, but its success hinges on clinical trial outcomes.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in share price volatility and funding secured for clinical trials.
Future Projections: Future growth depends entirely on Simufilam's clinical trial outcomes and regulatory approval. Analyst estimates are highly speculative and vary widely.
Recent Initiatives: Recent initiatives include ongoing Phase 3 clinical trials for Simufilam.
Summary
Cassava Sciences is a highly speculative investment, its success hinges on the success of Simufilam. The company has a novel mechanism of action, but it faces numerous risks, including clinical trial failures and regulatory disapproval, with strong competition from pharmaceutical giants like Biogen and Eli Lilly. While the potential reward is high, investors must carefully consider the significant risks involved. SAVA needs to prove Simufilam's efficacy and safety conclusively to succeed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cassava Sciences Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2000-07-14 | CEO, President & Director Mr. Richard Jon Barry | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://www.cassavasciences.com |
Full time employees 30 | Website https://www.cassavasciences.com | ||
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.